Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
Thomas R PieberRonnie AronsonUlrike HoevelmannJulie WillardLeona Plum-MörschelKim M KnudsenBenedikte BandakRamin TehranchiPublished in: Diabetes care (2022)
Dasiglucagon provided rapid and effective reversal of hypoglycemia in adults with type 1 diabetes, with safety and tolerability similar to those reported for reconstituted glucagon injection. The ready-to-use, aqueous formulation of dasiglucagon offers the potential to provide rapid and reliable treatment of severe hypoglycemia.
Keyphrases
- double blind
- clinical trial
- placebo controlled
- type diabetes
- open label
- phase iii
- phase ii
- glycemic control
- study protocol
- drug delivery
- loop mediated isothermal amplification
- randomized controlled trial
- combination therapy
- risk assessment
- climate change
- replacement therapy
- insulin resistance
- drug induced
- smoking cessation